An Insertion Within SIRPβ1 Shows a Dual Effect Over Alzheimer's Disease Cognitive Decline Altering the Microglial

José María García-Alberca1, Itziar de Rojas2,3, Elisabeth Sanchez-Mejias3,4

  • 1Alzheimer Research Center and Memory Clinic, Instituto Andaluz de Neurociencia (IANEC), Málaga, Spain.

Abstract

Insights

A structural variant in SIRPβ1 impacts Alzheimer's disease (AD) by altering amyloid-β (Aβ) clearance and microglial activation. This finding may inform therapeutic strategies targeting the TREM2-TYROBP pathway in AD.

Area of Science:

  • Neuroscience
  • Genetics
  • Immunology

Background:

  • Microglial dysfunction is a key factor in Alzheimer's disease (AD) pathogenesis.
  • This study investigates a specific germline variant in SIRPβ1, a receptor crucial for amyloid-β (Aβ) phagocytosis via TYROBP.

Purpose of the Study:

  • To determine the effect of a copy-number variant in SIRPβ1 on its expression.
  • To analyze how this variant influences the molecular mechanisms underlying AD.

Main Methods:

  • Evaluated copy-number variant proxy rs2209313 in longitudinal cohorts (GERALD, GR@ACE).
  • Examined hippocampal specimens from genotyped AD patients.
  • Conducted SIRPβ1 isoform-specific phagocytosis assays in HEK393T cells.

Main Results:

  • The SIRPβ1 insertion variant alters protein isoforms, impairing Aβ binding and TYROBP interaction.
  • Patients with the SIRPβ1 duplication (Dup/Dup) showed increased CSF t-Tau/Aβ ratio and higher AD risk.
  • Dup/Dup patients exhibited slower cognitive decline and reduced hippocampal degeneration, despite initial worse response to AD.
  • Duplication allele correlated with higher TREM2 expression and increased microglial activation.

Conclusions:

  • The SIRPβ1 internal duplication has dual effects on AD progression and MCI-to-dementia conversion, influencing microglial response to Aβ.
  • This SIRPβ1 variant could be a potential modulator of the TREM2-TYROBP pathway, relevant for AD pharmacotherapy.